Logo

American Heart Association

  129
  0


Final ID: Fri055

Machine Learning-Based Drug Screening Using Human iPS Cell-Derived Cardiac Tissues Identified A Novel Drug for Doxorubicin-Induced Cardiomyopathy

Abstract Body: Background: Cardiotoxicity is a life-threatening side effect of anti-cancer drugs like Doxorubicin (DOX). However, no effective treatments currently exist to mitigate drug-induced cardiac damage.
Research Questions: Can machine learning-based evaluation of sarcomere structures in human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes and contraction measurement in 3D functional cardiac tissues be applied for high-throughput screening for novel therapies?
Goals: To discover new therapeutics to prevent DOX-induced cardiac dysfunction.
Methods: We established a high-throughput screening assay integrating machine learning-based evaluation of cardiac damage in hiPSC-derived mature ventricular cardiomyocytes and functional evaluation of 3D mature cardiac tissues composed of hiPSC-ventricular cardiomyocytes and epicardial cells.
Results: DOX exposure caused sarcomere disorganization in 2D-cultured mature ventricular cardiomyocytes and contractile impairment in 3D cardiac tissues. We developed a supervised machine learning system to quantify sarcomere disorganization in 2D cardiomyocytes, enabling high-throughput screening and leading to the discovery of a novel drug that protects against DOX-induced sarcomere damage. The cardioprotective effect was validated in 3D mature cardiac tissues, where the drug improved contractile function under DOX exposure. Furthermore, in a DOX-induced cardiomyopathy mouse model, it also enhanced cardiac function and significantly increased survival.
Conclusion: This study highlights the potential of combining in vitro disease modeling with machine learning-based analysis for drug discovery. Our findings suggest that this novel drug could be an effective treatment for DOX-induced cardiomyopathy.
  • Funakoshi, Shunsuke  ( CiRA, Kyoto University , Kyoto , Japan )
  • Sasaki, Masako  ( CiRA, Kyoto University , Kyoto , Japan )
  • Kondo, Shigeru  ( Takeda Pharmaceutical Company Limit , Fujisawa , Japan )
  • Naka, Yuki  ( CiRA, Kyoto University , Kyoto , Japan )
  • Imahashi, Kenichi  ( Takeda Pharmaceutical Company Limit , Fujisawa , Japan )
  • Yoshida, Yoshinori  ( CiRA, Kyoto University , Kyoto , Japan )
  • Author Disclosures:
    Shunsuke Funakoshi: DO have relevant financial relationships ; Advisor:Orizuru Therapeutics:Active (exists now) | Masako Sasaki: No Answer | Shigeru Kondo: No Answer | Yuki Naka: No Answer | Kenichi Imahashi: No Answer | Yoshinori Yoshida: No Answer
Meeting Info:

Basic Cardiovascular Sciences 2025

2025

Baltimore, Maryland

Session Info:

Poster Session and Reception 3

Friday, 07/25/2025 , 04:30PM - 07:00PM

Poster Session and Reception

You have to be authorized to contact abstract author. Please, Login
Not Available